Brexanolone Reports Rapid, Durable Treatment for Post-Partum Depression

Novel injection therapy brexanolone has been proven to be a potentially rapid and durable treatment of post-partum depression (PPD) in new mothers, according to the results of a pair of phase 3 trials.

In recent analysis led by Samantha Meltzer-Brody, MD, of the Department of Psychiatry at University of North Carolina School of Medicine Chapel Hill, and funded by Sage Therapeutics—owner of the fast-track designated intravenous therapy—brexanolone showed significant benefits for patients with moderate to severe post-partum depression versus placebo.